After clinical studies conducted by the National Institutes of Health found that some children who received certain lots of PedvaxHIB (haemophilus b conjugate vaccine) developed lower than expected antibody levels, Merck & Co., Inc., issued a letter to physicians explaining that some children must be revaccinated.

This content is only available via PDF.
You do not currently have access to this content.